Pre-made Ontuxizumab benchmark antibody ( Whole mAb, anti-CD248 therapeutic antibody, Anti-CD164L1/TEM1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-405
Pre-Made Ontuxizumab biosimilar, Whole mAb, Anti-CD248 Antibody: Anti-CD164L1/TEM1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ontuxizumab is a humanized rabbit monoclonal antibody designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Ontuxizumab biosimilar, Whole mAb, Anti-CD248 Antibody: Anti-CD164L1/TEM1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA)|
|Conditions Active||Colorectal cancer;Malignant melanoma;Soft tissue sarcoma|
|Conditions Discontinued||Lymphoma;Solid tumours|